Mycophenolate Mofetil in Systemic Sclerosis

NCT ID: NCT00433186

Last Updated: 2011-03-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-03-31
• Study Completion Date: 2011-03-31

Brief Summary

This is a research study of an investigational product called Mycophenolate mofetil (MMF). The study is designed to establish the safety and potential benefit of MMF. MMF has proven one of the most effective medications to date for SLE and associated nephritis. It also appears to be active in polymyositis and dermatomyositis. This medication inhibits inosine monophosphate dehydrogenase, the rate-limiting enzyme in synthesis of guanosine nucleotides. It blocks the type II isoform found in activated lymphocytes more potently than the type I isoform inhibiting both T- and B-lymphocytes. In SSc, MMF has been tried after anti-thymocyte globulin in one small open label study with efficacy with a significant improvement in skin score. We will test the safety and efficacy of MMF in SSc. All study patients will receive the study medication. The effect of the study medication will be examined in two subgroups of patients: those with early or progressive skin disease (skin substudy) and those with muscle disease (muscle substudy). The change in modified Rodnan skin score (MRSS) and creatinine phosphokinase (CK) for, respectively, the skin and muscle substudies at 6 months after treatment will be compared to baseline values.

Detailed Description

Systemic sclerosis (SSc) is an autoimmune/connective tissue disease with complex pathogenesis involving immune system dysregulation, leading to fibrosis. Inflammatory and autoimmune aspects of this disease overlap systemic lupus erythematosus (SLE), a disease shown clearly to respond to MMF. Activated T-cells, the probable target of MMF in SLE, likely also play an important role in SSc pathogenesis. Evidence for this includes the similarity of SSc skin disease to chronic graft versus host disease, a disease in which T-cells play a critical role. MMF has proven one of the most effective medications to date for SLE and associated nephritis [1]. It also appears to be active in polymyositis and dermatomyositis, disease that also show significant overlap with SSc [2]. Myositis can also be a feature of SSc, suggesting that his disease manifestation might be particularly likely to respond to MMF. MMF inhibits inosine monophosphate dehydrogenase, the rate-limiting enzyme in synthesis of guanosine nucleotides. It blocks the type II isoform found in activated lymphocytes more potently than the type I isoform inhibiting both T- and B-lymphocytes [3]. In SSc, mycophenolate has been tried after anti-thymocyte globulin in one small open label study with efficacy with a significant improvement in skin score [4]. However, MMF has not been tried alone inSSc and has not been tried in muscle disease associated with SSc. In this study, we will test the safety and efficacy of MMF in SSc. In this study all study patients will receive the medication.

Conditions

Diffuse Cutaneous Systemic Sclerosis

Keywords

Scleroderma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

A

Mycophenolate

Group Type: EXPERIMENTAL

Mycophenolate Mofetil

Intervention Type: DRUG

Mycophenolate 3000 mg each day

Interventions

Mycophenolate Mofetil

Mycophenolate 3000 mg each day

Intervention Type: DRUG

Other Intervention Names

Cellcept

Eligibility Criteria

Inclusion Criteria

• Must meet the American College of Rheumatology criteria for systemic sclerosis with diffuse cutaneous disease or muscle involvement
• Patients must also meet one of the following criteria:

SKIN SUBSTUDY (20 patients)

• Be within 1 1/2 years of first non-Raynaud's disease manifestation.
• How progression of skin disease at some time over the past 6 months prior to study entry based on either documented increase in skin score or new areas of skin involvement or progression (no more than 10 patients total recruited)

OR, MUSCLE SUBSTUDY (10 patients)

• Have a serum creatinine phosphokinase (CK) greater than 2 times the upper limit of normal

• Patients entering the study on the basis of elevated CK must also have subjective and/or objective weakness; clinical evidence of cardiac, pulmonary or gastrointestinal disease as a complication of the patient¿s systemic sclerosis; or progressive skin disease.
• The total number of patients entered in criteria 2a and 2b (skin substudy) will be 20. Patients meeting both criteria 2c. and either 2a or 2b will first be recruited into the muscle substudy (by criteria 2c) until 10 patients have been recruited.
• Male or female patients >18 years of age.
• Able and willing to give written informed consent and comply with the requirements of the study protocol
• Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for 6 weeks after completion of treatment.
• Adequate renal function as indicated by Cr less than or equal to 3.0
• Adequate liver function, as indicated by SGOT and SGPT less than 2.5 times the upper limit of normal.
• Negative serum pregnancy test (for women of child bearing age)

Exclusion Criteria

• Treatment with any investigational agent within 4 weeks of screening or 5 half-lives of the investigational drug (whichever is longer).
• Ongoing use of high dose steroids (>10mg/day) or unstable steroid dose in the past 4 weeks.
• Receipt of a live vaccine within 4 weeks prior to randomization.
• Previous Treatment with MMF
• Treatment with immunosuppressive, cytotoxic or anti-fibrotic drug within 4 weeks of screening other than anti-malarial. This includes cyclophosphamide, azathioprine (Immuran), methotrexate or other immunosuppressive or cytotoxic medication.
• Treatment with cholestyramine within 1 week of trial entry.
• History of HIV, Hepatitis B and/or Hepatitis C, or evidence of Hepatitis B or C at screening.
• Moderate to severe hepatic impairment, Child-Pugh Class B or C.
• History of recurrent significant infection or history of recurrent bacterial infections.
• Known active bacterial, viral fungal mycobacterial, or other infection (including tuberculosis or atypical mycobacterial disease, but excluding fungal infections of nail beds) or any major episode of infection requiring hospitalization or treatment with i.v. antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening.
• Active gastrointestinal bleeding within 4 weeks of study entry or active serious gastrointestinal disease.
• Pregnancy (a negative serum pregnancy test will be performed for all women of childbearing potential within 14 days of treatment).
• Concomitant malignancies or previous malignancies within the last five years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
• A history of phenylketonuria, hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase, Lesch-Nyhan or Kelley-Seegmiller syndrome
• Allergy to polysorbate 80/Tween
• Subjects who are breastfeeding
• Moderately severe renal dysfunction as indicated by Cr >3.0, dipstick protein >3+, or patient on dialysis.
• Hemoglobin: < 8.5 gm/dL
• Platelets: < 100,000/mm
• AST or ALT >2.5 x Upper limit of normal unless related to muscle disease.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Aspreva Pharmaceuticals

INDUSTRY

Sponsor Role: collaborator

Boston University

OTHER

Sponsor Role: lead

Responsible Party

Boston University Medical Center

Principal Investigators

Robert Lafyatis, MD

Role: PRINCIPAL_INVESTIGATOR

Boston University School od Medicine Rheumatology Section

Locations

Boston University School of Medicine

Boston, Massachusetts, United States

Countries

United States

Other Identifiers

H-25973

Identifier Type: -

Identifier Source: org_study_id